Latest news with #regenerativemedicine
Globe and Mail
a day ago
- Business
- Globe and Mail
Timing Is Everything - Adia Nutrition Inc. Celebrates Florida's SB 1768 with Open Invitations to Adia Med Clinic
Winter Park, Florida--(Newsfile Corp. - June 19, 2025) - Adia Nutrition Inc., (OTCQB: ADIA) a rising leader in the $15.1 billion global stem cell industry, enthusiastically welcomes Florida's Senate Bill 1768. Signed into law last month and effective July 1, 2025, this transformative legislation permits physicians to offer stem cell therapies for orthopedics, wound repair, and pain management, expanding access to cutting-edge treatments while maintaining rigorous safety standards. Florida's SB 1768 To view an enhanced version of this graphic, please visit: SB 1768 authorizes medical and osteopathic doctors to perform, ensuring high-quality patient care through strict safety and efficacy requirements. This milestone establishes Florida as a frontrunner in regenerative medicine, responding to growing patient demand for innovative treatment options. Adia Nutrition Inc., through its Adia Med clinic in Winter Park, is eager to support this groundbreaking change. The company is collaborating with clinics across Florida, offering comprehensive assistance to navigate the new law. Adia provides unmatched support for stem cell trials, research, and procedures, enabling clinics to seamlessly integrate these therapies. Committed to excellence, Adia delivers industry-leading customer service and relationship management to foster strong partnerships that enhance patient outcomes. Starting July 1, 2025, Adia Med of Winter Park will mail invitations to celebrate the passage of SB 1768, inviting the community to visit the clinic and explore its advanced regenerative therapies. For a limited time, Adia Med will offer free consultations to showcase its state-of-the-art facilities and personalized care. "We're thrilled about SB 1768 and its impact on patient care," said Larry Powalisz, CEO of Adia Nutrition Inc. "Our team is dedicated to helping clinics implement stem cell therapies with top-tier support and service. I personally invite everyone-whether you're in Florida or anywhere across the country-to visit Adia Med in Winter Park for world-class treatment and to experience the future of regenerative medicine." Clinics interested in adopting stem cell therapies are encouraged to contact Adia Nutrition Inc. for expert guidance. By partnering with Adia, clinics gain access to premium stem cell and exosome products backed by Adia's exceptional expertise. For more information, to explore partnership opportunities, or to schedule a visit to Adia Med, contact Adia Nutrition Inc. at ceo@ or 321-788-0850, or visit Adia remains dedicated to advancing healthcare through innovative stem cell solutions and meaningful collaborations. THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.: Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
Yahoo
2 days ago
- Business
- Yahoo
Polydeoxyribonudeotide (PDRN) Market to Surge with Anti-Aging & Regenerative Therapies Demand: Valuates Reports
BANGALORE, India , June 18, 2025 /PRNewswire/ -- Polydeoxyribonudeotide (PDRN) Market is Segmented by Type (Powder, Solution), by Application (Mesotherapy, Bone Injection & Dermal Fillers, Pharmaceutical, Cosmetic) Wound Healing Products and Others): Global Opportunity Analysis and Industry Forecast, 2024-2031. The global market for Polydeoxyribonudeotide (PDRN) was valued at USD 72.1 million in the year 2024 and is projected to reach a revised size of USD 855 million by 2031, growing at a CAGR of 43.0% during the forecast period. Claim Your Free Report: Major Factors Driving the Growth of Polydeoxyribonudeotide (PDRN) Market: The Polydeoxyribonucleotide (PDRN) market is witnessing accelerated growth due to increasing applications in aesthetics, wound healing, and regenerative medicine. With strong demand from cosmetic clinics, dermatologists, and biotech firms, PDRN is becoming a staple in modern therapeutic protocols. Solution and powder forms cater to both convenience and customization needs. Growing investments in R&D, rising consumer awareness, and favorable regulatory developments further bolster market momentum. The rise of anti-aging consciousness, medical tourism, and combination therapies ensures a strong future outlook. As more markets adopt biologic-based treatments, PDRN is poised to expand across global healthcare and cosmetic industries. Unlock Insights: View Full Report Now! TRENDS INFLUENCING THE GROWTH OF THE POLYDEOXYRIBONUDEOTIDE (PDRN) MARKET Solution-based PDRN formulations are playing a pivotal role in expanding the market due to their convenience, fast absorption, and targeted therapeutic efficiency. These liquid formats are widely used in mesotherapy, dermatological treatments, and regenerative injections, where rapid delivery to specific skin or tissue layers is crucial. Clinics and aesthetic centers prefer solution-based PDRN as they reduce preparation time and ensure consistent dosing. Moreover, solution formulations are compatible with a wide range of medical devices and allow for combination therapies with other active agents. Their versatility and effectiveness in promoting tissue repair, improving skin texture, and reducing inflammation significantly enhance their appeal, thereby propelling demand within the growing PDRN market. Powder-based PDRN products are gaining traction in the market due to their long shelf life, stability, and flexibility in formulation. These products are typically reconstituted with sterile water or saline before use, offering precision and control in dosage based on the treatment area. Powdered PDRN is especially popular in cosmetic clinics and research applications, where practitioners may customize concentrations for individual patients. The demand for minimally invasive aesthetic procedures has surged, and powdered formats meet the requirements for microneedling, skin rejuvenation, and scar treatment. Additionally, powdered PDRN reduces the risk of microbial contamination, making it a preferred option in sterile clinical environments, thus supporting market growth. The cosmetic industry is a major driver of the PDRN market due to its increasing reliance on biologically active ingredients for anti-aging, skin repair, and aesthetic treatments. PDRN, known for stimulating cell regeneration and collagen production, is widely incorporated in procedures like mesotherapy, skin boosters, and serums. As consumer preference shifts toward non-surgical and regenerative beauty solutions, cosmetic clinics and dermatologists are adopting PDRN-based products to deliver visibly youthful skin with minimal downtime. High demand from Asia, especially South Korea and Japan, where skin care innovations lead global trends, also contributes to rapid growth. Thus, cosmetics remain a cornerstone segment, fueling PDRN market expansion. The growing demand for regenerative therapies in aesthetics is significantly boosting the PDRN market. Consumers are increasingly seeking non-invasive treatments that provide natural, long-lasting results. PDRN, derived from salmon DNA, promotes tissue repair and cellular regeneration, making it ideal for skin rejuvenation, wound healing, and scar treatment. Its integration into mesotherapy and facial injectables aligns with patient demand for biologically active, safer alternatives to synthetic fillers. This regenerative trend is especially prominent in Asia and gradually expanding in Western markets, where clinics are offering combination treatments that include PDRN. The shift toward healing-based beauty solutions strongly supports market growth in the aesthetic domain. PDRN's effectiveness in accelerating wound healing is a key factor driving its medical adoption. It enhances tissue repair, reduces inflammation, and improves skin regeneration, making it suitable for treating chronic wounds, burns, ulcers, and post-surgical scars. Dermatologists use PDRN in creams, gels, and injections to treat skin conditions such as eczema, acne scars, and atopic dermatitis. Its anti-inflammatory properties and ability to boost microcirculation improve patient outcomes and reduce recovery times. As healthcare providers prioritize tissue repair in both clinical and homecare settings, the demand for PDRN in therapeutic dermatology continues to grow, positively impacting the overall market. The global anti-aging market is expanding rapidly, creating new opportunities for PDRN-based solutions. PDRN's ability to stimulate fibroblast activity, improve skin elasticity, and reduce fine lines has made it a key ingredient in injectable serums and creams. Clinics offer skin booster treatments using PDRN to restore hydration and radiance, particularly in the face, neck, and hands. As consumers seek safer alternatives to Botox and dermal fillers, PDRN stands out for its regenerative approach with fewer side effects. With aging populations and beauty consciousness rising worldwide, particularly among millennials and older adults, the anti-aging segment remains a strong growth pillar for the PDRN market. PDRN is increasingly used in combination therapies, which is driving innovation and market growth. It is often paired with hyaluronic acid, peptides, vitamins, and growth factors to enhance overall treatment efficacy. Such combinations offer synergistic effects—while PDRN accelerates cellular repair, other agents provide hydration, nourishment, and tightening. This integration allows for comprehensive solutions addressing multiple skin concerns, including dullness, sagging, and pigmentation. Aesthetic practitioners prefer these formulations for customized treatments tailored to patient needs. The success of combination-based injectable products has led to new launches and broader adoption, pushing the PDRN market to evolve rapidly in both medical and cosmetic fields. Medical tourism, particularly in Asia-Pacific countries like South Korea, Thailand, and Malaysia, is contributing significantly to the PDRN market. These destinations are known for offering high-quality aesthetic and regenerative treatments at lower costs, attracting international patients. Clinics in these countries often market advanced therapies including PDRN-based injectables and facials as part of their service portfolio. The rising global interest in Korean beauty standards has also helped promote PDRN usage in non-invasive skincare. Coupled with government support and private investment in healthcare tourism, the influx of patients from Europe, the Middle East, and North America is boosting demand for sterile, effective PDRN products. Claim Yours Now! POLYDEOXYRIBONUDEOTIDE (PDRN) MARKET SHARE ANALYSIS Global key players of Polydeoxyribonudeotide (PDRN) include HTL Biotechnology and ReaLi Tide Biological. The top two players hold a share over 44%. China is the largest market, with a share of about 40%, followed by Europe and South Korea, with 24% and 33%, separately. The PDRN market is dominated by Asia-Pacific, particularly South Korea, China, and Japan, where aesthetic and regenerative medicine are deeply integrated into healthcare. China and South Korea are leading the Asia pacific market with widespread adoption of PDRN in dermatology and beauty clinics. In terms of product type, Powder is the largest segment, occupying a share of 65%, and in terms of application, Mesotherapy has a share of about 31%. Key Players: Mastelli BR PHARM BNF Solution Ruijiming Biological HENGYU BIOPH ReaLi Tide Biological HTL Biotechnology PharmaResearch Co., Ltd. Humedix Dongkook BMI KOREA Purchase Regional Data: SUBSCRIPTION We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans. DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS! Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) Market Medical Grade Polydeoxyribonucleotide (PDRN) Market The global market for Cosmetic Grade Polydeoxyribonudeotide (PDRN) was valued at USD 45.7 million in the year 2024 and is projected to reach a revised size of USD 550 million by 2031, growing at a CAGR of 43.3% during the forecast period. The global market for Mesenchymal Stem Cells was valued at USD 226 million in the year 2024 and is projected to reach a revised size of USD 306 million by 2031, growing at a CAGR of 4.5% during the forecast period. The global Platelet Rich Plasma market is projected to grow from USD 302.1 million in 2024 to USD 342.2 million by 2030, at a Compound Annual Growth Rate (CAGR) of 2.1% during the forecast period. The global Stem Cell Therapy market size was USD 685 million in 2024 and is forecast to a readjusted size of USD 2373 million by 2031 with a CAGR of 19.7% during the forecast period 2025-2031. The global market for Anti-Inflammatory Cytokine was valued at USD 28920 million in the year 2024 and is projected to reach a revised size of USD 44960 million by 2031, growing at a CAGR of 6.6% during the forecast period. The global market for Exosomes Skincare was valued at USD 423 million in the year 2024 and is projected to reach a revised size of USD 796 million by 2031, growing at a CAGR of 9.6% during the forecast period. Polynucleotides Injectable Market The global Regenerative Medicine Market revenue was USD 33370 million in 2022 and is forecast to a readjusted size of USD 115660 million by 2029 with a CAGR of 19.2% during the review period (2023-2029). The global market for Skin Substitutes was valued at USD 1635 million in the year 2023 and is projected to reach a revised size of USD 4665 million by 2030, growing at a CAGR of 16.8% during the forecast period. DISCOVER OUR VISION: VISIT ABOUT US! Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs. Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs. To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources. GET A FREE QUOTE Valuates Reportssales@ U.S. Toll-Free Call 1-(315)-215-3225WhatsApp: +91-9945648335 Website: Blog: Pinterest: Twitter: Facebook: YouTube: Logo - View original content to download multimedia: SOURCE Valuates Reports Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
BioRestorative Announces Share Repurchase Program
MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ('BioRestorative', 'BRTX' or the 'Company') (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026. "This share repurchase program reflects our confidence in the strength of our clinical development pipeline and the future outlook of our business,' said Lance Alstodt, Chief Executive Officer of BioRestorative. 'There is no question in our minds that BioRestorative has great science, assets and people. As such, we believe our current share price does not reflect the intrinsic value of the company, particularly in light of our recent clinical and operational progress. Accordingly, we believe this program provides us with an opportunity to enhance long-term shareholder value.' The repurchases may be made from time to time in the open market, through privately negotiated transactions, or by other means in accordance with applicable securities laws. The timing, number, and value of shares repurchased under the program will be at the discretion of the Company's management and will depend on a variety of factors, including market conditions, share price, and other corporate considerations. The share repurchase program may be modified, suspended or terminated at any time at the Company's discretion and does not obligate the Company to acquire any amount of common stock. About BioRestorative Therapies, Inc. BioRestorative ( develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration ('FDA') Investigational New Drug ('IND') clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain. • Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells ('BADSC') to generate brown adipose tissue ('BAT'), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss. • BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements. CONTACT: Stephen KilmerInvestor RelationsDirect: (646) 274-3580 Email: skilmer@
Yahoo
3 days ago
- Business
- Yahoo
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the 'Biotherapies and Bioproduction of Innovative Therapies' call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates. Accelerating the transition to late-stage clinical production and commercialization This funding marks a key step in the company's industrial scale-up. It will notably allow for the scale-up of its exosome bioproduction technology in 50L GMP bioreactors, reaching a production level compatible with late-stage clinical phases and market launch. 'The French government 's support through the France 2030 'Biotherapies and Bioproduction' call is a strong recognition of our technology and industrial ambition. Thanks to this funding, we will secure a robust and scalable bioproduction process, which is essential to advance through late-stage clinical phases and prepare the market entry of our future proprietary or co-developed treatments,' said Jeanne Volatron, CEO of EVerZom. Exosomes at the heart of the development of promising new biotherapies Exosomes are tiny biological vesicles (30 to 150 nanometers) naturally secreted by cells. They play a key role in intercellular communication, transporting proteins, messenger RNAs, and other functional biomolecules between cells. EVerZom leverages exosomes derived from mesenchymal stem cells, known for their regenerative and immunomodulatory properties. Compared to the cells themselves, exosomes offer numerous advantages: increased stability, reduced variability, enhanced patient safety, and simplified logistics (direct hospital storage and immediate availability). EVerGel, EVerZom's first drug candidate for Crohn's disease EVerZom's flagship program, EVerGel, combines exosomes with an innovative hydrogel biomaterial, enabling prolonged release at the site of complex perianal fistulas—a debilitating condition associated with Crohn's disease that affects nearly 2 million patients worldwide. Initial preclinical results are highly promising: in a porcine model close to the human condition, EVerGel achieved complete healing in 87.5% of cases after 4 weeks, compared to just 12.5% in the control group. Thanks to these results, the drug candidate could enter clinical trials as early as 2026, with a target commercialization date for 2030. High potential far beyond the targeted indications Ultimately, the potential of exosome therapies to regenerate tissue and modulate inflammatory processes opens the door to new applications in a variety of fields, including neurodegenerative diseases, age-related disorders, and regenerative cosmetics. In this context, EVerZom has established around twenty global partnerships with players in human health, animal health, and cosmetics. Press contact : Florence Portejoie, FP2COM, 06 07 76 82 83, fportejoie@ About EVerZom Founded in 2019, EVerZom develops exosome-based treatments derived from mesenchymal stem cells, combined with biomaterials for targeted applications. With a proprietary technology for the production and purification of exosomes, EVerZom aims to address unmet medical needs in chronic inflammatory and degenerative diseases. The company relies on cutting-edge scientific expertise, a network of industrial and academic partners, and a development model focused on pharmaceutical quality and industrialization. This €3 million funding is part of the France 2030 plan, a French government initiative endowed with €54 billion to support breakthrough innovations and the emergence of technology champions in strategic sectors such as biotechnology. About France 2030 ✔ Embodies a dual ambition: to sustainably transform key sectors of our economy (health, energy, automotive, aerospace, and space) through technological innovation, and to position France not just as a player but as a leader in the world of tomorrow. From basic research to the emergence of an idea through to the production of a new product or service, France 2030 supports the entire innovation lifecycle up to industrialization. ✔ Is unprecedented in its scope: €54 billion are being invested to help our companies, universities, and research organizations successfully transition in these strategic sectors. The goal is to enable them to competitively tackle ecological and attractiveness challenges and foster the emergence of future leaders in our fields of excellence. France 2030 has two transversal objectives: dedicating 50% of its spending to the decarbonization of the economy and 50% to emerging players carrying innovations that are not harmful to the environment (in line with the Do No Significant Harm principle). ✔ Is implemented collectively: designed and deployed in consultation with economic, academic, local, and European stakeholders to determine strategic orientations and flagship actions. Project leaders are invited to submit their applications through open, rigorous, and selective procedures to benefit from State support. ✔ Is managed by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Environment and Energy Management Agency (ADEME), the National Research Agency (ANR), Bpifrance, and the Banque des Territoires. More information: | @SGPI_avenir About the 'Innovations in Biotherapies and Bioproduction' call for projects The 'Innovations in Biotherapies and Bioproduction' call for projects is a support mechanism within the framework of the 'Biotherapies and Bioproduction of Innovative Therapies' acceleration strategy of France 2030, led by the Health Innovation Agency within the General Secretariat for Investment. Its objective is to catalyze and sustain excellence in biotherapy research by accelerating technology transfer and ensuring a constant flow of innovations from bench to bedside. About Bpifrance Bpifrance finances businesses at every stage of their development with loans, guarantees, and equity. It supports their innovation and international projects. Bpifrance also backs their export activities through a broad range of products. Advisory services, training, networking, and acceleration programs for startups, SMEs, and mid-caps are also part of the offering. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, single, and efficient contact to support them and help them meet their challenges. More information: - - Follow us on X (formerly Twitter): @Bpifrance - @BpifrancePresse and on LinkedIn Attachment Everzom_PR_Winner_France_2030_VDEF
Yahoo
4 days ago
- Health
- Yahoo
Home Run! Adia Med of Winter Park's AHCA Triumph Brings Insurance-Covered Healing to Patients
Winter Park, Florida--(Newsfile Corp. - June 16, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), a leading innovator in regenerative medicine and nutritional supplements, is thrilled to announce that its state-of-the-art clinic, Adia Med of Winter Park, has received full approval from the Agency for Health Care Administration (AHCA). This milestone allows Adia Med of Winter Park to accept insurance, marking a significant advancement in providing accessible, life-changing treatments to patients across Florida. To view an enhanced version of this graphic, please visit: The AHCA approval positions Adia Med of Winter Park as a premier destination for innovative therapies, including Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Multiple Sclerosis (MS) and other autoimmune conditions, as well as therapeutic plasma exchange (TPE), and other breakthrough medical treatments. By accepting insurance, Adia Nutrition can now work directly with patients to advocate for coverage, making transformative treatments more affordable and accessible. "This AHCA approval is a game-changer for Adia Nutrition and our patients," said Larry Powalisz, Chief Executive Officer of Adia Nutrition. "Being able to accept insurance means we can partner with patients to fight for their right to coverage for innovative therapies like aHSCT, which have the potential to dramatically improve quality of life. We're committed to breaking down financial barriers and delivering world-class care." Located in Winter Park, Florida, Adia Med of Winter Park, which opened in January 2025, is equipped to deliver cutting-edge regenerative treatments tailored to individual patient needs. The clinic's approval by AHCA underscores its compliance with Florida's rigorous healthcare standards, reinforcing Adia Nutrition's entry in the $4.9 trillion health-care insurance market. Historical | CMS Patients interested in exploring insurance-covered treatment options at Adia Med of Winter Park are encouraged to fill out the contact form at For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
